Universal HPLC detector offers near nanogram sensitivity

Published: 6-May-2010
Manufacturing Research & Development Analysis

NQAD is said to be a major advance in high-performance liquid chromatography detection

Dorton Analytical, a UK supplier of laboratory equipment, says its ultra-sensitive, universal Nano Quantity Analyte Detector (NQAD) is a major advance in high-performance liquid chromatography detection.

The NQAD is a different kind of aerosol-based detector for HPLC, the company says. Based on Condensation Nucleation (CNLSD) technology, the NQAD has the ability to detect sub-nanogram levels.

Benefiting from ultra-high sensitivity, the detector is suitable for searching for drug impurities, degradation products, excipients and when industrial hygiene is a concern. Both easy and hard-to-measure compounds can be quantified accurately with minimal sample preparation, the company says.

The NQAD detector also offers a wide dynamic range with superior linearity compared with other aerosol-based detectors. Chromophores and fluorophores are not needed for detection, thereby eliminating or decreasing the need for compound derivatisation. The detector is optimised for use in UHPLC, HPLC and SFC.

The company says it is easy to install and operate and therefore ideal for use in any laboratory.

See more

You may also like

Manufacturing

Setting standards for polymer and protein characterisation

Read more
SEC-3010 triple detector system uses GPC/SEC

Trending Articles

  1. FDA issues first cGMP warning letter citing AI misuse in pharmaceutical manufacturing A Michigan-based lab has become the subject of the FDA's first dedicated enforcement action on artificial intelligence misuse in drug manufacturing — a landmark event with far-reaching implications for cGMP compliance across the pharmaceutical supply chain
  2. Epitopea receives MHRA approval for first-in-human trial of RNA vaccine for ovarian cancer The company has received regulatory approval from the MHRA and Regional Ethics Committee to initiate its OVACT Phase I/Ib clinical trial of CryptiVax-1001, an off-the-shelf mRNA immunotherapy targeting high-grade serous ovarian cancer
  3. Japanese pharma companies shifting to earlier CDMO outsourcing as peptide complexity increases Neuland Laboratories has reported a notable shift in Japanese pharmaceutical outsourcing patterns during the past 12-24 months, with companies engaging CDMOs earlier in the development cycle
  4. UK REACH reform falls short as industry warns of £500m+ compliance bill The UK chemicals industry has condemned the Government's long-awaited response to the UK REACH Alternative Transitional Registration model consultation, arguing it does little to support growth or innovation
  5. See. Try. Believe. Experience the Lyza 7000 FTIR with a 70-day risk free trial Laboratories can now evaluate the Lyza 7000 FTIR spectrometer in their own environment through a new 70-day, no-cost, no-risk trial program. The initiative allows teams to run real samples, follow existing SOPs, and fully explore the instrument’s capabilities before making a purchase decision

Upcoming event

CHEMUK 2026

20–21 May 2026 | Conference and Exhibition | Birmingham, UK See all

You may also like

Manufacturing

Setting standards for polymer and protein characterisation

SEC-3010 triple detector system uses GPC/SEC
Research & Development

Scientists develop new technique to fight antimicrobial resistance

The team of researchers from the University of Leicester have developed a new technique to sequence phage genomes from individual plaques and hopes to use it to build fully characterised libraries of bacteriophages, expanding the number of candidates available to tackle drug-resistant infections
Research & Development

Lancet Oncology Commission launches to examine future of academic cancer clinical trials amid funding and regulatory pressures

A global coalition of clinical investigators and patient representatives has launched the Lancet Oncology Commission to address the value and challenges of independent academic cancer clinical trials, amid growing concerns over regulatory complexity, limited public funding and the need for new international collaboration models
Manufacturing

Almac highlights SDS-PAGE approach for residual protein determination in new white paper

New white paper explores robust analytical method for residual protein detection in biocatalytic API manufacturing
Manufacturing

Reliable, high-performance pump for HPLC and UHPLC

Biotech Fluidics announce the ASI 540 – an affordable, standalone solvent delivery pump - design optimised for liquid chromatography applications
Manufacturing

BD and Suttons Creek collaborate to streamline combination product development for pharma and biotech

The new strategic collaboration will help pharmaceutical and biotech companies reduce development risk and regulatory complexity across drug-device combination products, including biologics and GLP-1 therapies
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

UK clinical trial reforms come into force in largest regulatory overhaul in 20 years

The MHRA and Health Research Authority are implementing the most significant package of clinical trial regulatory reforms in more than two decades, introducing faster assessment routes for lower-risk trials and mandatory registration of trial results
Subscribe now